UroToday

ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
UroToday

ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
UroToday

ASCO GU 2026: A Phase II Trial of Cabozantinib in Relapsed Refractory Germ Cell Tumors

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
UroToday

ASCO GU 2026: REJOICE-PanTumor01: A Phase 2 Signal-Seeking Study of Raludotatug Deruxtecan in Patients with Advanced or Metastatic Gynecologic or Genitourinary Tumors

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
UroToday

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...
UroToday

ASCO GU 2026: Discussant: miR-371a-3p for MRD Detection in Clinical Stage I Testicular Germ Cell Tumors

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...
UroToday

ASCO GU 2026: Biomarker Analysis from the Phase 2 LITESPARK-013 Study of Two Different Belzutifan Doses in Participants with Advanced Clear Cell RCC

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
UroToday

Suprapubic vs Urethral Catheters for Neurogenic Bladder - Frank Lin

Frank Lin reviews suprapubic versus urethral catheterization for neurogenic bladder patients unable to perform intermittent catheterization. Systematic review of over 2,000 patients showed comparable ...
UroToday

Phase III Evaluation of Mevrometostat + Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-1 & MEVPRO-2)

Phase III Evaluation of Mevrometostat + Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-1 & MEVPRO-2) A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN ...
UroToday

MEVPRO-3: Phase III trial of mevrometostat plus enzalutamide (versus placebo plus enzalutamide) in metastatic castration-sensitive prostate cancer (mCSPC)

Condition: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate Study ID: NCT07028853 ...
UroToday

ESMO 2025: Targeting Androgen Receptor Alterations in Prostate Cancer

(UroToday.com) The 2025 ESMO annual meeting featured a biomarker-based personalization in metastatic prostate cancer session and a presentation by Dr. Alice Bernard-Tessier discussing targeting ...
UroToday

SNMMI 2025: Clinical Trial Protocol Update – FLEX-MRT: A Randomized Phase 2 Trial of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer session and a presentation by Dr. Adrien Holzgreve discussing a clinical trial protocol update of FLEX-MRT, a randomized phase 2 ...